ProBioGen, a service and technology provider for complex therapeutic glycoproteins, and Chiome Bioscience, a Japanese antibody discovery and development company, have signed a service and license agreement under which ProBioGen will apply its enhanced cancer cell-killing technology GlymaxX to Chiome’s LIV-1205, an antibody clinical candidate program. ProBioGen will develop a stable GlymaxX cell line, followed by process development and GMP manufacturing of the ADCC-enhanced cancer stem cell a...